Advertisement

Journal of Neuro-Oncology

, Volume 105, Issue 3, pp 467–474 | Cite as

Revisiting the role of molecular targeted therapies in patients with brain metastases

  • Dionysis Papadatos-Pastos
  • Udai Banerji
Topic Review

Abstract

Brain metastases (BM) are treated with surgical resection when feasible. Unfortunately this occurs only in a small subset of patients. The optimal treatment for patients with intracranial metastases non amenable to surgical resection has not been identified. Radiotherapy improves symptom control and survival but long-term local control has been poor. Conventional chemotherapies have generally produced disappointing results possibly due to their limited ability to penetrate the blood brain barrier. Therefore, newer treatments are required for patients with unresectable BM. Targeted therapies such as bevacizumab, erlotinib, gefitinib, sunitinib and sorafenib, are all licensed and have demonstrated improved survival in patients with metastatic disease. In this review we will present current data on targeted therapies that have been approved for the treatment of malignant tumours and we discuss the evidence of their use in patients with BM.

Keywords

Targeted Brain Metastases Bevacizumab Erlotinib Sunitinib 

References

  1. 1.
    Posner JB, Chernic NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579–592PubMedGoogle Scholar
  2. 2.
    Schiff (2001) Single brain metastases. Curr Treat Options Neurol 3:89–99Google Scholar
  3. 3.
    van den Bent MJ (2001) The diagnosis and management of brain metastases. Curr Opin Neurol 14:717–723PubMedCrossRefGoogle Scholar
  4. 4.
    Carden CP, Agarwal R, Saran F, Judson I (2008) Eligibility of patients with brain metastases for phase 1 trials: time for a rethink? Lancet Oncol 9:1012–1017PubMedCrossRefGoogle Scholar
  5. 5.
    Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumour patients: natural history and results of treatment. Cancer 48:384–394PubMedCrossRefGoogle Scholar
  6. 6.
    Posner J (1977) Management of central nervous system metastases. Sem Oncol 4:81–91Google Scholar
  7. 7.
    Bradley KA, Mehta MP (2004) Management of brain metastases. Semin Oncol 31:693–701PubMedCrossRefGoogle Scholar
  8. 8.
    Gaspar LE, Mehta MP, Patchell RA (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:17–32PubMedCrossRefGoogle Scholar
  9. 9.
    Miller KD, Weathers T, Haney LG et al (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072–1077PubMedCrossRefGoogle Scholar
  10. 10.
    Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 280:1485–1489PubMedCrossRefGoogle Scholar
  11. 11.
    Linskey ME, Andrews DW, Asher AL et al (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45–68PubMedCrossRefGoogle Scholar
  12. 12.
    Lesser GJ (1996) Chemotherapy of cerebral metastases from solid tumours. Neurosurg Clin North Am 7:527–536Google Scholar
  13. 13.
    Mehta MP, Paleologos NA, Mikkelsen T et al (2010) The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:71–83PubMedCrossRefGoogle Scholar
  14. 14.
    Olson J, Paleologos NA, Gaspar LE et al (2010) The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96:115–142PubMedCrossRefGoogle Scholar
  15. 15.
    Riese DJ, Stern DF (1998) Specificity within the EGF family/ErbB receptor family signalling network. Bioessays 20:41–48PubMedCrossRefGoogle Scholar
  16. 16.
    Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292–302PubMedCrossRefGoogle Scholar
  17. 17.
    Emens LA, Davidson NE (2004) Trastuzumab in breast cancer. Oncology 18:1117–1128; discussion 1131–1132, 1137–1138Google Scholar
  18. 18.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over express HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  19. 19.
    Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: M77001 study group. J Clin Oncol 23(19):4265–4274PubMedCrossRefGoogle Scholar
  20. 20.
    Romond E (2005) Joint analysis of NSABP-B-31 and NCCTG-N9831. American society of clinical oncology annual Meeting, OrlandoGoogle Scholar
  21. 21.
    Piccart-Gebhart M (2005) HERA trial. American society of clinical oncology Annual Meeting, OrlandoGoogle Scholar
  22. 22.
    Yardley DA, Kaufman PA, Mayer M et al (2007) RegistHER: patients characteristics and time course of CNS metastases in patients with HER2 positive metastatic breast cancer. Breast Cancer Res Treat 106:2007 (supp 1; abstract 6049)Google Scholar
  23. 23.
    Souglakos J, Vamvakas L, Apostolaki S et al (2006) Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumour cells and with HER2/neu status. Breast Cancer Res 8:R36. doi: 10.1186/bcr1516 PubMedCrossRefGoogle Scholar
  24. 24.
    Altaha R, Crowell E, Hobbs G et al (2005) Increased risk of brain metastases in patients with HER2/neu positive breast carcinoma. Cancer 103:442–443PubMedCrossRefGoogle Scholar
  25. 25.
    Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastases after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663PubMedCrossRefGoogle Scholar
  26. 26.
    Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for central nervous system metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944PubMedCrossRefGoogle Scholar
  27. 27.
    Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRefGoogle Scholar
  28. 28.
    Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMedGoogle Scholar
  29. 29.
    Shmueli E, Wigler N, Inbar M et al (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379–382PubMedCrossRefGoogle Scholar
  30. 30.
    Stemmler HJ, Kahlert S, Siekiera W et al (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 over expressing metastatic breast cancer. Breast 15:219–225PubMedCrossRefGoogle Scholar
  31. 31.
    Yau T, Swanton C, Chua S et al (2006) Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196–201PubMedCrossRefGoogle Scholar
  32. 32.
    Pinder MC, Chang H, Broglio KR et al (2007) Trastuzumab treatment and the risk of central nervous system metastases. J Clin Oncol 25:36 (supp 18; abstr 1018)CrossRefGoogle Scholar
  33. 33.
    Lower EE, Drosick DR, Blau R et al (2003) Increased rate of brain metastases with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 4:114–119PubMedCrossRefGoogle Scholar
  34. 34.
    Leyland-Jones B (2009) Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases. J Clin Oncol 27:5278–5286PubMedCrossRefGoogle Scholar
  35. 35.
    Bria E, Cuppone F, Fornier M et al (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomised trials. Breast Cancer Res Treat 109:231–239PubMedCrossRefGoogle Scholar
  36. 36.
    Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2 positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drug 18:23–28CrossRefGoogle Scholar
  37. 37.
    Bartsch R, Rottenfusser A, Wenzel C et al (2007) Trastuzumab prolongs survival in patients with brain metastases from HER2 positive breast cancer. J Neurooncol 85:311–317PubMedCrossRefGoogle Scholar
  38. 38.
    Church DN, Modgil R, Guglani S et al (2008) Extended survival in women with brain metastases from HER2 over expressing breast cancer. Am J Clin Oncol 31:250–254PubMedCrossRefGoogle Scholar
  39. 39.
    Dawood SS, Broglio K, Esteva FJ et al (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19:1242–1248PubMedCrossRefGoogle Scholar
  40. 40.
    Lichinitser M, Ganshina I, Zhukova L et al (2007) HER-2 over expressed breast cancer and brain metastases. Breast J 16:19 (supp 1, abstr P26)Google Scholar
  41. 41.
    Sawrie SM, Meredith RF, Spencer SA et al (2007) HER2-neu status as a predictor of survival in patients in patients with brain metastases from primary breast adenocarcinoma. J Clin Oncol 25:36 (supp 18, abstr 1016)Google Scholar
  42. 42.
    Nam BH, Kim SY, Han HS et al (2007) Survival gain by trastuzumab therapy after onset of intracranial metastases in patients with metastatic breast cancer. Breast Cancer Res Treat 106:187 (supp 1, abstr 4061)Google Scholar
  43. 43.
    Grossi PM, Ochiai H, Archer GE et al (2003) Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514–5520PubMedGoogle Scholar
  44. 44.
    Kinoshita M, McDannold N, Jolesz FA et al (2006) Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 103:1719–1723CrossRefGoogle Scholar
  45. 45.
    Braen AP, Perron J, Tellier P et al (2010) A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol 3:259–267CrossRefGoogle Scholar
  46. 46.
    Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-over expressing metastatic breast cancer: a case report. Anticancer Drug 19:832–836CrossRefGoogle Scholar
  47. 47.
    Platini C, Long J, Walter S et al (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778–780PubMedCrossRefGoogle Scholar
  48. 48.
    Laufman LR, Forsthoefel KF (2002) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:316CrossRefGoogle Scholar
  49. 49.
    Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus Capecitabine for HER2 positive advanced breast cancer. N Engl J Med 26:2733–2744CrossRefGoogle Scholar
  50. 50.
    Polli JW, Humphreys JE, Harmon KA et al (2008) The role of efflux and uptake transporters in lapatinib disposition and drug interaction. Drug Metab Dispos 36:695–701PubMedCrossRefGoogle Scholar
  51. 51.
    Gril B, Palmieri D, Bronder JL et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092–1103PubMedCrossRefGoogle Scholar
  52. 52.
    Lin NU, Carey LA, Liu MC et al (2008) Phase 2 trial of lapatinib fro brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993–1999PubMedCrossRefGoogle Scholar
  53. 53.
    Lin NU, Dieras V, Paul D et al (2009) Multicenter phase 2 study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459Google Scholar
  54. 54.
    Shepherd FA, Rodrigues Pereira J et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132Google Scholar
  55. 55.
    Langer CJ, Mehta MP et al (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207–6219PubMedCrossRefGoogle Scholar
  56. 56.
    Moyer JD, Barbacci EG, Iwata KK et al (1997) Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57(21):4838–4848PubMedGoogle Scholar
  57. 57.
    Albanell J, Rojo F, Averbuch S et al (2002) Pharmacodynamic studies of the epidermal growth factor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1):110–124PubMedCrossRefGoogle Scholar
  58. 58.
    Nishi N, Kawai S, Yonezawa T et al (2006) Effect of gefitinib on brain metastases from non-small cell lung cancer. Neurol Med Chir (Tokyo) 46(10):504–507CrossRefGoogle Scholar
  59. 59.
    Sakai M, Ishikawa S, Ito H et al (2006) Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 11(3):243–245PubMedCrossRefGoogle Scholar
  60. 60.
    Stemmler HJ, Weigert O, Krych M et al (2005) Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. Anticancer Drugs 16(7):747–749PubMedCrossRefGoogle Scholar
  61. 61.
    Mairovitz A, Staub E, Le Floch H et al (2009) Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months. Rev Pneumol Clin 65(5):318–321PubMedCrossRefGoogle Scholar
  62. 62.
    Altavilla G, Arrigo C, Santarpia MC et al (2008) Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol 90(1):31–33PubMedCrossRefGoogle Scholar
  63. 63.
    Von Pawel J, Wagner H, Duell T et al (2008) Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie 31(3):123–126CrossRefGoogle Scholar
  64. 64.
    Popat S, Hughes S, Papadopoulos P et al (2007) Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56(1):135–137PubMedCrossRefGoogle Scholar
  65. 65.
    Namba Y, Kijima T, Yokota S et al (2004) Gefitinib in patients with brain metastasis from non-small cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6:123–128PubMedCrossRefGoogle Scholar
  66. 66.
    Hotta K, Kiura K, Ueoka H et al (2004) Effect of gefitinib on brain metastases in patients with advanced non-small cell lung cancer. Lung Cancer 46:255–261PubMedCrossRefGoogle Scholar
  67. 67.
    Wu C, Li YL, Wang ZM et al (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57:359–364PubMedCrossRefGoogle Scholar
  68. 68.
    Kim EJ, Lee DH, Choi Y et al (2009) Epidermal growth receptor tyrosine kinase inhibitors as a first-line therapy for non-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastases. Lung Cancer 65:351–354PubMedCrossRefGoogle Scholar
  69. 69.
    Ceresoli GL, Cappuzzo F, Gregorc V et al (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15:1042–1047PubMedCrossRefGoogle Scholar
  70. 70.
    Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy. Radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72:257–266PubMedCrossRefGoogle Scholar
  71. 71.
    Bonner JA, Harari PM, Giralt JL et al (2004) Cetuximab (Erbitux TM) prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck: a phase III study of high dose radiation therapy with and without cetuximab. Proc Am Soc Clin Oncol Abstract no. 5507Google Scholar
  72. 72.
    Ma S, Xu Y, Deng Q et al (2009) Treatment of brain metastases from non-small-cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65:198–203PubMedCrossRefGoogle Scholar
  73. 73.
    Ferrara N et al (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRefGoogle Scholar
  74. 74.
    Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803PubMedCrossRefGoogle Scholar
  75. 75.
    Giantonio BJ et al (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23(suppl 2, abstr 2) American Society of Clinical Oncology annual meetingGoogle Scholar
  76. 76.
    Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550Google Scholar
  77. 77.
    Carden CP, Larkin JC, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10:624–630PubMedCrossRefGoogle Scholar
  78. 78.
    Socinski MA, Langer CJ, Huang JE et al (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27:5255–5261PubMedCrossRefGoogle Scholar
  79. 79.
    Besse B, Lasserre SF, Compton P (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16(1):269–278PubMedCrossRefGoogle Scholar
  80. 80.
    Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740PubMedCrossRefGoogle Scholar
  81. 81.
    Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745PubMedCrossRefGoogle Scholar
  82. 82.
    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 356:125–134CrossRefGoogle Scholar
  83. 83.
    Massard C, Zonierek J, Gross-Goupil M et al (2010) Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 21(5):1027–1031PubMedCrossRefGoogle Scholar
  84. 84.
    Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5):1272–1280PubMedCrossRefGoogle Scholar
  85. 85.
    Demetri et al (2006) Improved survival and sustained clinical benefit with SU11248 in patients with GIST after failure of imatinib mesylate (IM) therapy in a phase 3 trial. ASCO Gastrointestinal Cancers Symposium , abstract no. 8Google Scholar
  86. 86.
    Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 1010:757–763CrossRefGoogle Scholar
  87. 87.
    Paryna S, Peng J (2006) Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4:21Google Scholar
  88. 88.
    Gore ME, Hariharan S, Porta C et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117:501–509Google Scholar
  89. 89.
    Culine S, Bekradda M, Kramar A et al (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83:2548–2553PubMedCrossRefGoogle Scholar
  90. 90.
    Kalkanis SN, Kondziolka D, Gaspar LE et al (2010) The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:33–43PubMedCrossRefGoogle Scholar
  91. 91.
    Papadatos-Pastos D, Blanco-Codesido M, Banerji U, et al (2010) Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. 2010 ASCO Annual Meeting Proceedings, J Clin Oncol 28(15) suppl (May 20 Supplement): 2516Google Scholar
  92. 92.
    Yan DF, Yan SX, Yang JS et al (2010) Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. BMC Cancer 10:49PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.Royal Marsden HospitalSuttonUK

Personalised recommendations